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2 
Abstract 24 
Insulin resistance is associated with impaired endothelial regeneration in response to 25 
mechanical injury. We recently demonstrated that insulin-like growth factor binding protein-1 26 
(IGFBP1) ameliorated insulin resistance and increased nitric oxide generation in the 27 
endothelium. In this study, we hypothesised that IGFBP1 would improve endothelial 28 
regeneration and restore endothelial reparative functions in the setting of insulin resistance. 29 
In mice heterozygous for deletion of insulin receptors (IR+/-), endothelial regeneration after 30 
femoral artery wire injury was enhanced by transgenic expression of human IGFBP1. This 31 
was not explained by altered abundance of circulating myeloid angiogenic cells. Incubation of 32 
human endothelial cells with hIGFBP1 increased integrin expression and enhanced their 33 
ability to adhere to and repopulate denuded human saphenous vein ex vivo. In vitro, induction 34 
of insulin resistance by TNFα significantly inhibited endothelial cell migration and proliferation. 35 
Co-incubation with hIGFBP1 restored endothelial migratory and proliferative capacity. At the 36 
molecular level, hIGFBP1 induced phosphorylation of focal adhesion kinase, activated RhoA 37 
and modulated TNFα-induced actin fibre anisotropy. Collectively, the effects of hIGFBP1 on 38 
endothelial cell responses and acceleration of endothelial regeneration in mice indicate that 39 
manipulating IGFBP1 could be exploited as a putative strategy to improve endothelial repair 40 
in the setting of insulin resistance.  41 
Précis 42 
IGFBP1 ameliorated insulin resistance-induced defects in re-endothelialization in vivo and 43 
impairment of endothelial migration and proliferation in vitro via FAK and RhoA activation. 44 
 45 
 46 
  47 
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Introduction 48 
Functional and structural integrity of the endothelial monolayer plays a critical role in 49 
vascular homeostasis. Damage to the endothelium by exposure to vascular risk factors or 50 
mechanical trauma predisposes to a range of pathologies including atherosclerosis (1), 51 
bypass graft failure (2), restenosis (3) and stent thrombosis (4). Regeneration of damaged 52 
endothelium following injury is essential to prevent adverse remodelling and is mediated by 53 
two broad mechanisms: proliferation and migration of local endothelial cells (5,6) and 54 
recruitment of circulating cells to the injured vessel (7). The latter include endothelial colony 55 
forming cells (ECFC) which are fully committed to the endothelial lineage and can form 56 
mature vascular networks; and myeloid angiogenic cells (MAC) which exhibit a 57 
macrophage/monocyte-like phenotype and contribute to endothelial repair through the 58 
secretion of pro-angiogenic cytokines (8).  59 
Type 2 diabetes mellitus is associated with both dysfunctional vascular endothelial 60 
regeneration and a high risk of cardiovascular events. Insulin resistance has emerged as a 61 
major player in diabetes-related vasculopathy, not least through its strong association with 62 
endothelial dysfunction (9). Although diabetes is strongly associated with defective vascular 63 
repair, we identified that insulin resistance per se is sufficient to jeopardise endothelial 64 
regeneration after arterial injury (10). Endothelial regeneration following mechanical wire-65 
induced arterial injury was impaired in mice heterozygous for deletion of the insulin receptor 66 
(IR+/-) - explained at least in part through reduced mobilisation of MACs (10). Recognition of 67 
the adverse impact of insulin resistance on endothelial repair processes led us to question 68 
whether insulin sensitization might enhance endothelial regeneration in the setting of insulin 69 
resistance.  70 
Insulin-like growth factor binding protein-1 (IGFBP1) is one of a family of circulating proteins 71 
which confer spatial and temporal regulation of IGF bioavailability but which can also 72 
orchestrate cellular responses independent of their modulation of IGF actions (11). At the 73 
structural level, IGF-independent actions of IGFBP1 have been ascribed to an Arg-Gly-Asp 74 
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(RGD) motif within its C-terminal domain which can interact with cell surface integrins and 75 
promote migratory responses in certain cell types (12,13). However, potential effects of 76 
IGFBP1 on migratory responses have not previously been studied in endothelial cells.    77 
From the functional perspective, an inhibitory effect of insulin on hepatic IGFBP1 synthesis 78 
has led to IGFBP1 being implicated in glucose regulation (14). The circulating concentration 79 
of IGFBP1 has been proposed as a biomarker of insulin sensitivity (15,16). In 80 
epidemiological studies, low plasma IGFBP1 concentrations are strongly predictive of the 81 
prospective development of type 2 diabetes (17–19). We recently identified direct actions of 82 
the RGD-domain of IGFBP1 in augmenting insulin signalling and insulin-stimulated glucose 83 
uptake (20).  Human studies also indicate a link between low circulating IGFBP1 84 
concentration and risk of cardiovascular disease (16,21). Conversely, in the setting of acute 85 
myocardial infarction IGFBP1 levels predict mortality but the effect may be confounded by 86 
association with elevated levels of co-peptin (22,23).  87 
We have demonstrated in preclinical studies that IGFBP1 plays a favourable role in both 88 
insulin sensitivity and vascular function (24). Transgenic expression of human IGFBP1 in 89 
mice was associated with whole-body and vascular insulin sensitization, increased basal 90 
nitric oxide (NO) bioavailability, lower blood pressure and reduced susceptibility to 91 
atherosclerosis (24). 92 
Here we hypothesised that increasing the concentration of IGFBP1 would ameliorate the 93 
detrimental effects of insulin resistance on endothelial repair. To investigate this, we 94 
assessed endothelial regeneration in IR+/- mice expressing human IGFBP1 subjected to 95 
arterial injury and evaluated the effects of hIGFBP1 on the functional properties of 96 
endothelial cells in vitro.  97 
 98 
 99 
  100 
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Material and Methods 101 
Chemicals and antibodies 102 
The antibodies used for immunoblotting are listed in Table 1. Chemicals were purchased 103 
from Sigma Chemical/Sigma-Aldrich (St. Louis, MO), unless otherwise specified. Human 104 
IGFBP1 and IGF-1 were purchased from GroPep (Adelaide, Australia). Recombinant 105 
hIGFBP1 was expressed in Expi293F cells (Life Technologies) using the SUMOStar 106 
expression system (LifeSensors) and purified as described previously (20). Site-directed 107 
mutagenesis of the hIGFBP-1expressing plasmid was performed using the QuikChange 108 
Lightning kit (Agilent Technologies) using primers 5′-TCCAGAGATCTGGGGAGACCC-3′ 109 
and 5′-GGGTCTCCCCAGATCTCTGGA-3′ to generate the WGD hIGFBP1 expression 110 
construct. 111 
 112 
Animals. 113 
IR+/- mice (25) were bred in house from founder animals originating from the Medical Research 114 
Council Mammalian Genetics Unit (Harwell, Oxfordshire, U.K.). hIGFBP1 transgenic (tg) mice 115 
were originally generated by Crossey et al at King’s College London (26), and subsequently 116 
backcrossed to a C57BL/6J background for multiple generations.  IR+/- and hIGFBP1 mice 117 
were inter-crossed to generate IR+/-hIGFBP1tg mice.  Animals were maintained as 118 
heterozygotes on a C57BL/6 background in a conventional animal facility with a 12-h light/dark 119 
cycle and received a standard laboratory diet.  Male WT, IR+/-, hIGFBP1tg, and IR+/-hIGFBP1tg 120 
littermate mice (aged 12–16 weeks) were compared. Genotyping was performed using PCR 121 
on ear notch genomic DNA, with the primers described previously (24,27). All procedures were 122 
approved by the Animal Welfare and Ethical Review Committee at the University of Leeds and 123 
were carried out in accordance with the Animals (Scientific Procedures) Act 1986 Amendment 124 
Regulations 2012.  125 
Plasma IGFBP1 concentration 126 
 
 
6 
Circulating concentration of IGFBP1 was measured in plasma of non-fasted animals using a 127 
commercially available ELISA kit according to the manufacturer’s instructions (IGFBP1 ELISA 128 
kit ab100539, Abcam, Cambridge, UK).  129 
Vascular injury. 130 
Mice were anaesthetised with isoflurane (2.5–5%) before a small incision was made in the 131 
mid-thigh to permit isolation of the femoral artery (28). Following an arteriotomy made using 132 
iris scissors (World-Precision Instruments, Sarasota, FL), a 0.014-inch-diameter angioplasty 133 
guide wire with tapered tip (Hi-torque Cross-it XT, Abbott-Vascular, Abbott, IL), was 134 
introduced. The angioplasty guide wire was advanced 3cm, and three passages were 135 
performed per mouse, resulting in complete arterial denudation. The guide wire was removed 136 
and the suture was tightened rapidly. The vessel was then ligated, and the skin was closed 137 
with a continuous suture. The contralateral artery underwent an identical sham operation, 138 
without passage of the wire. Animals received postoperative analgesia with buprenorphine 139 
(0.25 mg/kg).  140 
Assessment of endothelial regeneration by en face microscopy. 141 
Mice were anesthetized five days after wire injury, and 50 μL of 0.5% Evans blue dye injected 142 
into the inferior vena cava. The mice were perfused/fixed with 4% paraformaldehyde in PBS 143 
before the femoral arteries (injured and uninjured) were harvested.  The vessels were opened 144 
longitudinally.  The areas stained and unstained in blue were measured in a 5mm injured 145 
segment beginning 5mm distal to the aortic bifurcation, and the percentage areas were 146 
calculated using ImageProPlus7.0 software (Media Cybernetics, Bethesda, MD). 147 
Mononuclear cell isolation and culture. 148 
Isolation of mononuclear cells (MNCs) from 1 mL of blood, obtained from the vena cava under 149 
terminal anaesthesia, was by Histopaque-1083 (Sigma) density gradient centrifugation. MNCs 150 
were seeded on fibronectin 24-well plates (BD Biosciences) at a density of 1×106 cells/well. 151 
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Cells were cultured in EC growth (EGM-2) medium supplemented with EGM-2 Bullet kit 152 
(Lonza, Basel, Switzerland) in addition to 20% FCS.  153 
Spleens obtained from mice under terminal anaesthesia were minced mechanically. MNCs 154 
were isolated by density gradient centrifugation, as described above. After washing steps, 155 
cells were seeded on fibronectin 24-well plates at a seeding density of 8×106 cells/well and 156 
cultured as described above.  157 
Tibias and femurs were flushed three times in DMEM with a 26-gauge needle to collect bone 158 
marrow (BM). MNCs were isolated by density gradient centrifugation as described above. After 159 
washing steps, cells were seeded on fibronectin 24-well plates at a seeding density of 1×106 160 
cells/well and cultured as described above.  161 
Myeloid Angiogenic Cell characterization. 162 
After four days incubation at 37°C in 5% CO2, gentle washing with PBS discarded non-163 
adherent cells and adherent cells were re-suspended in medium. At day 7, attached cells from 164 
peripheral blood, spleen, and BM were stained for the uptake of 1,1’-dioctadecy-3,3,3′,3′-165 
tetramethyllindocarbocyanine-labeled acetylated low-density lipoprotein (DiI-Ac-LDL) 166 
(Molecular Probes, Invitrogen, Carlsbad, CA) and lectin from Ulex europaeus FITC conjugate 167 
(Sigma). Cells were first incubated with DiI-Ac-LDL at 37°C for 3h and later fixed with 4% 168 
paraformaldehyde for 10 minutes. Cells were washed and reacted with lectin for 1h. After 169 
staining, cells were quantified by examining 10 random high-power fields (HPF) and double-170 
positive cells were identified as MACs.  171 
MAC function: adhesion assay. 172 
To assess adhesion, 50,000 MACs were re-suspended in EGM-2 medium, plated onto 24-173 
well plates coated with indicated substrates, and incubated for 1 h at 37°C. After washing 174 
three times with PBS, attached cells were counted. Adhesion was evaluated as the mean 175 
number of attached cells per HPF (×100).  176 
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Fluorescence-activated cell sorter enumeration of Sca-1/Flk-1 cells. 177 
Murine saphenous vein blood samples (100µL) were incubated with PharmLyse (BD 178 
Biosciences, San Jose CA) at room temperature.  After centrifugation, mononuclear cells 179 
(MNCs) were re-suspended in fluorescence-activated cell sorter (FACS) buffer and incubated 180 
with FcR blocker (BD Biosciences) at 4°C.  As per protocol, appropriate volumes of the 181 
antibodies, or their respective isotype controls, were added for 10 minutes at 4°C: fluorescein 182 
isothiocyanate (FITC) anti-mouse Sca-1 and PE anti-mouse Flk-1 (BD Biosciences). 183 
Enumeration of APCs was performed using flow cytometry (BD FACS Calibur) to quantify 184 
dual-stained Sca-1/Flk-1 cells.  Isotype control specimens were used to define the threshold 185 
for antigen presence and to subtract non-specific fluorescence.  The cytometer was set to 186 
acquire 100,000 events within the lymphocyte gate, defined by typical light scatter properties. 187 
Ex-vivo Saphenous vein adhesion assay 188 
Saphenous vein segments were obtained from patients undergoing coronary artery bypass 189 
graft surgery at Leeds Teaching Hospitals NHS Trust, Leeds, UK following ethical approval. 190 
Human coronary artery endothelial cells (HCAECs) (Promocell, Heidelberg, Germany) stained 191 
with CellTracker CM-Dil (Invitrogen, Oregon, USA) were incubated for one hour at a fixed 192 
density (250,000 cells/ml) in full (20%) ECGM suspension with either control vehicle or 193 
hIGFBP1 (500ng/mL) (GroPep, Australia).  After one hour, 50,000 cells from each treatment 194 
group were seeded onto a denuded segment of human saphenous vein and incubated for 5 195 
minutes.  After 5 minutes, the cell suspension was gently washed with PBS, Hoecht stain was 196 
then added to the saphenous vein segment and finally re-suspended in full (20%) ECGM. 197 
Images were obtained by confocal microscopy of the vein segments, assessing the number 198 
of cells adhering to the saphenous vein matrix. 199 
Endothelial cell adhesion assays 200 
The potential for hIGFBP1 to modulate adhesion was investigated in adhesion assays 201 
performed with HCAECs.  HCAEC suspensions (100,000 cells/mL) were seeded onto sterile 202 
 
 
9 
glass cover slips.  Vehicle-treated wells contained 1% FCS and treatment wells contained 203 
hIGFBP1 (500ng/mL in 1% FCS).  Adherent cells in one vehicle-treated well and one 204 
corresponding IGFBP-1 well were fixed after 2 hours, 4 hours and 6 hours of incubation at 205 
37C in 4% paraformaldehyde and stained with Haematoxylin & Eosin for 1 minute.  Finally, 206 
the cover slips were mounted onto microscope slides using glycerol gelatin and 10 random 207 
fields containing the adherent cells were counted at 400x magnification.  208 
To investigate the potential for hIGFBP1 to modulate adhesion to individual extracellular matrix 209 
components, HUVECS were seeded at 50,000 cells per well of 24 well plates coated with 210 
fibronectin (Corning, 354411), collagen I (Thermo fisher Scientific, A1142802), collagen IV 211 
(Corning, 734-0127) or vitronectin (coated in house, using Novoprotein, C395 at 1µg/well). 212 
and incubated for 30mins at 37°C. Cells were washed once with PBS and attached cells were 213 
counted. Adhesion was evaluated as the mean number of attached cells per HPF (×40). The 214 
involvement of focal adhesion kinase (FAK) was investigated using the FAK inhibitor PZ0117 215 
(Sigma-Aldrich; 100 nmol/L).  216 
 217 
Integrin-Mediated Cell Adhesion  218 
Cell surface subunit or heterodimer integrins were quantified using an integrin-mediated cell 219 
adhesion array kit (ECM532, Millipore). HCAECs were grown to confluence in T-75 flasks.  220 
Once confluent, cells were harvested using Gibco® Cell Dissociation Buffer.  HCAECs were 221 
co-incubated with or without hIGFBP1 (500ng/mL) for one hour before 100,000 cells were 222 
added to the integrin antibody-coated and control wells and incubated for 2h at 37°C. Unbound 223 
cells were then washed off and the adherent cells stained. The optical density of nuclear stain 224 
extracts was measured at 540nm (OD540nm) on a MRX TC 2 microplate reader (DYNEX 225 
Technologies, U.K.). 226 
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 227 
Migration assays 228 
Migration of HCAECs and Human Umbilical Vein Endothelial Cells (HUVECs) was 229 
investigated in twelve-well plates using a modification of a ‘scratch wound’ method. Briefly, 230 
duplicate scratches were made with a sterile 1 ml pipette tip in confluent endothelial 231 
monolayers (having been quiesced in medium containing 1% FBS for 16h), reference points 232 
etched in the dishes and images were captured (0h).  Cells were then exposed to hIGFBP1 233 
(500ng/mL), TNF-alpha (10ng/mL) or both in combination with 10% FBS endothelial cell 234 
growth medium in a tissue-culture incubator for an additional 48h. Further images were then 235 
captured by aligning the dishes with the reference point made at time 0h, and images were 236 
acquired at 24h and 48h.  Quantification was achieved by counting the number of cells which 237 
had migrated beyond a fixed distance from the initial wound edge. 238 
 239 
Endothelial cell migration was also studied using a modified Boyden chamber technique, as 240 
we have described previously (29).  HCAECs or HUVECS (100,000) were loaded in the upper 241 
chamber in medium supplemented with 20% FBS. The lower chamber contained 20% FBS 242 
with hIGFBP1 (500ng/mL) or VEGF (50ng/mL). After incubation for 6 h at 37°C in a tissue-243 
culture incubator, duplicate membranes were processed and evaluated by counting migrated 244 
cells on the underside of the membrane in 10 random fields under high power (×400) light 245 
microscopy. 246 
Cell proliferation assays 247 
HCAEC and HUVEC proliferation assays were performed by seeding cells in 24-well culture 248 
plates at a density of 20,000 cells per well in full endothelial growth medium (20% FBS).  After 249 
30-32h, incubated cells were quiesced in medium containing 1% FBS for 16 hours. Cells were 250 
then exposed to control growth medium (20% FBS) and hIGFBP1 (500ng/mL), TNF-alpha 251 
(0.1ng/mL) or both in combination.  Medium and chemicals were replaced on days 2 and 4 252 
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and viable cell number determined in triplicate wells on day 5 using Trypan Blue and a 253 
haemocytometer. In additional experiments, proliferation was assessed in HUVEC by an EdU 254 
(5-ethynyl-2’-deoxyuridine) kit in accordance with the manufacturer’s instructions (Click-iT 255 
EdU Alexa Fluor 488 Imaging Kit; C10337; Invitrogen). The proliferative response to hIGFBP1 256 
(500ng/mL) +/- IGF-1 (18nmol/L) (Gropep, Adelaide, Australia) were studied.  Involvement of 257 
focal adhesion kinase (FAK) was investigated using the FAK inhibitor PZ0117 (Sigma-Aldrich; 258 
100 nmol/L).  259 
 260 
Western blotting for p-FAK and p-Akt 261 
HUVEC after four hours of serum-starvation were incubated +/- hIGFBP1 or WGD-hIGFBP1 262 
(500ng/mL) for 15 minutes.  Protein was extracted in lysis buffer and quantified using the 263 
protein BCA assay (Sigma-Aldrich). Then, 30µg of protein were separated by electrophoresis 264 
through 4–12% SDS-PAGE gels (Invitrogen Life Technologies, Carlsbad, CA) and blotted onto 265 
polyvinylidene fluoride membranes.  Immunoblots were performed as previously (30) 266 
described  using antibodies listed in Table 1.  Inhibition by TNF- of insulin-stimulated Akt 267 
phosphorylation was determined in HUVEC. Cells were incubated with TNF- (10ng/mL) for 268 
the indicated durations (30-120 mins) and then stimulated with insulin (100nmol/L 15 mins) to 269 
assess the effects of TNF- on insulin-induced Akt phosphorylation.  270 
RhoA activity assay 271 
HCAECs were seeded at 100,000 cells/well into 6 well plates.  On reaching 80% confluence 272 
cells were serum starved overnight and then treated with hIGFBP1 for the following times: 0 273 
minutes, 10 minutes, 20 minutes and 40 minutes.  After treatment, the medium was aspirated 274 
and washed thrice with ice-cold PBS being especially careful to remove all residual PBS.  Cells 275 
were then lysed with 120 µL of ice-cold lysis buffer (1:100 of Protease inhibitor:lysis buffer), 276 
harvested and transferred into microcentrifuge tubes on ice.  The samples were centrifuged 277 
at 10,000g, 4 °C for 2 minutes.  20µL of lysate were taken off and stored at 4 °C for protein 278 
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quantification and the remainder used to assess RhoA activity assay by the RhoA G-LISA kit 279 
(Cytoskeleton, Inc., Denver, Colorado, USA) according to the manufacturer’s instructions.   280 
Endothelial cell actin fibre anisotropy assessment 281 
HCAECs were seeded at 12,000 cells/well in gelatin-coated Labtek 8-well chamber slides then 282 
grown for 48h in ECGM/20% FCS. Subsequently cells were incubated for 24h in 283 
ECGM/10%FCS alone or with either hIGFBP1 (500ng/mL), TNF-α (10ng/mL Peprotech) or 284 
both proteins. Prior to fixation, cells were washed once with PBS at 37ºC then treated with 3% 285 
paraformaldehyde in PBS (warmed to 37ºC) for 20 min. To remove unreacted 286 
paraformaldehyde, cells were washed three times with PBS, incubated for 10 min with 50mM 287 
NH4Cl in PBS then washed three further times with PBS. Prior to staining, cells were 288 
permeabilised for 4 minutes with 0.2% triton X 100 in PBS followed by three PBS washes, 289 
then blocked for 30 minutes with 0.2% fish skin gelatin in PBS (FSG/PBS).  Actin filaments 290 
were stained with FITC-phalloidin (Enzo Life science) at 1.5 ug/ml final concentration in 291 
FSG/PBS for 1h followed by 3 washes with FSG/PBS, one wash in PBS and one wash in 292 
deionized water.  Cells were mounted with Duolink In Situ Mounting Medium with DAPI 293 
(Sigma) and actin filaments and cell nuclei were imaged on Delta Vision widefield 294 
deconvolution system (Applied Precision), and Zeiss LSM 700 laser-scanning confocal 295 
microscopes. On the Delta Vision microscope images were acquired with a 40x 1.35NA oil 296 
objective at 0.2 µm z-intervals at 1024x1024 pixel resolution images were processed with 10 297 
cycles of deconvolution (conservative model) before generation of an 8-bit maximum intensity 298 
projection for analysis. On the LSM700 microscope images were acquired with a 40x1.3NA 299 
oil objective and were scanned at 1024x1024 pixel resolution at 8-bits per pixel. Optical section 300 
thickness was set at 1 Airy unit and z-step at 0.48 µm.  301 
The Fibril Tool plug-in for Image J (31) was used to analyse the anisotropy of actin fibres in 302 
FITC-phalloidin images. Whole cells with intact nuclei were included in the analysis. Cells were 303 
subdivided into 2-8 sub-regions (corresponding to major fibre cluster alignments and avoiding 304 
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the nucleus and saturated areas) using the polygon tool and anisotropy for each cell was 305 
calculated as an area- weighted average of sub-regions. 306 
Data analysis 307 
Results are expressed as mean±SEM. Data were demonstrated to be normally distributed 308 
using the Shapiro-Wilk test. Comparisons within groups were made using paired Students t-309 
tests and between groups using unpaired Students t tests or repeated measures ANOVA with 310 
post-hoc Newman-Keuls tests, as appropriate. P<0.05 was considered statistically significant. 311 
 312 
  313 
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Results 314 
Transgenic expression of hIGFBP1 ameliorates the detrimental effects of insulin resistance 315 
on endothelial regeneration. 316 
Endothelial regeneration was quantified in murine femoral arteries five days after wire-317 
induced arterial injury, which we determined as the time-point at which re-endothelialisation 318 
was maximally impaired in insulin resistant mice (10). There was no difference in endothelial 319 
regeneration between hIGFBP1tg and wild type animals [Fig 1A&B]. As whole body 320 
metabolic phenotype is not altered in hIGFBP1tg mice (24) this indicates that increasing 321 
hIGFBP1 does not alter endothelial regeneration in metabolically normal animals. In 322 
contrast, impaired endothelial regeneration observed in IR+/- mice was significantly improved 323 
by overexpression of hIGFBP1 [Fig 1 A&C]. Plasma concentration of IGFBP1 was 324 
significantly increased in hIGFBP1tg mice and was similarly increased in insulin resistant IR+/- 325 
mice overexpressing hIGFBP1 (supplementary fig 1). 326 
Enhanced endothelial regeneration in hIGFBP1 expressing insulin resistant mice is not 327 
attributable to changes in abundance or function of circulating angiogenic progenitor cells. 328 
Endothelial regeneration following mechanical injury is accomplished by an orchestrated 329 
cellular response comprising the proliferation and migration of vessel-wall resident 330 
endothelial cells and the recruitment of circulating cells with angiogenic potential (7).  We 331 
have previously reported that impaired endothelial regeneration in IR+/- mice is associated 332 
with reduced abundance of circulating MACs, and decreased mobilisation of Sca-1+/Flk-333 
1+cells from bone marrow (10). We therefore investigated whether changes in abundance of 334 
MACs were responsible for enhanced endothelial regeneration in mice expressing hIGFBP1 335 
in the current study. We found no difference between WT and hIGFBP1tg mice in abundance 336 
of blood-derived MACs (fig 2A). The yield of circulating MACs was reduced in IR+/- mice but 337 
was not significantly modified by the expression of hIGFBP1 (fig 2A). The yield of MACs 338 
from bone-marrow and spleen was similar in all groups of mice (fig 2B-C). Adhesion of 339 
MACs to fibronectin-coated plates was uninfluenced by genotype (fig 2D). The abundance of 340 
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Sca-1+/Flk-1+ cells in the mononuclear cell fraction of blood was measured by flow cytometry 341 
and was similar in all groups of mice (fig 2E).  342 
Acute exposure to hIGFBP1 increases adherence of human endothelial cells to human 343 
vessels and upregulates availability of integrins.  344 
To examine whether hIGFBP1 directly modulates the reparative function of native 345 
endothelial cells, we first examined the effects of short term incubation with hIGFBP1 on the 346 
adhesive properties of endothelial cells. We investigated the ability of human coronary artery 347 
endothelial cells (HCAEC) to adhere to endothelium-denuded segments of human 348 
saphenous vein. We found that HCAEC were adherent to denuded saphenous vein after five 349 
minutes (fig 3A). Pre-incubation with hIGFBP1 (500ng/mL 1 hour) resulted in a significant 350 
increase in the number of adherent cells (fig 3B-C). In contrast to the modulatory effect of 351 
hIGFBP1 on adhesion to a denuded vessel, incubation with hIGFBP1 had no effect on 352 
adhesion of HCAEC to uncoated glass coverslips (fig 3D). Because adhesion of endothelial 353 
cells to extracellular matrix is critically dependent on interaction of matrix components (e.g. 354 
fibronectin) with cell surface integrins (32), we quantified functional integrin abundance using 355 
an integrin-mediated cell adhesion array kit. We found that incubation of HCAEC with 356 
hIGFBP1 (500ng/mL 1 hour) lead to significant increase in the cell surface abundance of α2 357 
and αV integrin subunits and of αVβ3 and α5β1 integrins (fig 3E-F). To further characterise the 358 
upregulation of endothelial cell adhesion by hIGFBP1, we investigated the effects of 359 
hIGFBP1 on adherence of HUVEC to individual extracellular matrix (ECM) components in 360 
vitro.  There was a trend to increased adhesion on several matrices but we were not able to 361 
identify a dominant ECM constituent to which hIGFBP1 preferentially increased adhesion 362 
(supplementary fig 2). 363 
hIGFBP1 ameliorates insulin-resistance induced endothelial migratory and proliferative 364 
defects in human endothelial cells 365 
Regeneration of injured endothelium by local resident endothelial cells is dependent on their 366 
ability to migrate and proliferate to form a neo-endothelium. In linear wound assays, we 367 
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found that incubation with hIGFBP1 (500ng/mL; 1 hour) did not influence migration of either 368 
human umbilical vein endothelial cells (HUVEC) or HCAEC (fig 4A-B). To mimic the 369 
biochemical milieu to which endothelial cells are exposed in insulin resistant states in vivo, 370 
we pre-incubated HUVEC with tumor necrosis factor (TNF)-α to inhibit the insulin signaling 371 
pathway (fig 4C-D). Incubation with TNF-α (10ng/mL) inhibited migration of HUVEC (fig 4E) 372 
and HCAEC (fig 4F), which was ameliorated in both types of endothelial cell by co-373 
incubation with hIGFBP1 (500ng/mL) (fig 4E-F). We also investigated whether 374 
hIGFBP1increased migration of endothelial cells in a modified Boyden chamber assay. 375 
There was no difference in migration of HUVEC or HCAEC indicating that hIGFBP1 does not 376 
act as a chemotactic stimulus for endothelial cells (fig 5A-B). Similarly, hIGFBP1 did not 377 
modulate the migratory response of HCAEC to the potent chemotactic stimulus vascular 378 
endothelial growth factor (fig 5C). 379 
In both HUVEC and HCAEC, incubation with hIGFBP1 led to a trend to increased cell 380 
proliferation assessed by cell counting which did not reach statistical significance (fig 6A-B). 381 
Incubation with TNF-α inhibited proliferation of HCAEC in a concentration-dependent 382 
manner (fig 6C). The anti-proliferative effects of TNF-α were ameliorated by incubation of 383 
HCAEC with hIGFBP1 (fig 6D).   384 
Pro-reparative effects of hIGFBP1 on the endothelium are dependent on its RGD domain 385 
and focal adhesion kinase. 386 
To further explore the molecular basis of the pro-reparative effects of hIGFBP1 in the 387 
endothelium, we employed an EdU assay to quantify the effects of hIGFBP1 on proliferative 388 
responses in HUVEC. We found a significant dose-dependent increase in cell proliferation at 389 
hIGFBP1 concentrations of 100-500ng/mL (Supplementary fig 3). As IGFBPs are known to 390 
act variably as IGF-modulators or independently of IGF contingent on context, we next 391 
compared the effects of IGF-1 and hIGFBP1 on endothelial cell proliferation. Equimolar 392 
concentrations of IGF-1 and hIGFBP1 both individually stimulated proliferation to a similar 393 
extent, but there was no evidence of an additive effect (fig 7A). We then mutated the RGD 394 
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domain of IGFBP1, responsible for binding to cell surface integrins, to a non-functional WGD 395 
domain incapable of integrin binding (20). Stimulation of endothelial cell proliferation by 396 
hIGFBP1 was ameliorated by RGD -> WGD mutation (fig 7B&C). Focal adhesion kinase 397 
(FAK) is an important signalling node downstream of integrins and is known to mediate 398 
proangiogenic signalling in endothelial cells (33). Inhibition of FAK abrogated the stimulatory 399 
effect of hIGFBP1 on cell proliferation (Figure 7D) and reduced adhesion to collagen IV in 400 
the presence of hIGFBP1 (suppl fig 2F).  401 
Acute exposure to hIGFBP1 leads to phosphorylation of focal adhesion kinase, activation of 402 
RhoA and modulation of F-actin organisation in endothelial cells. 403 
Because the RGD motif of hIGFBP1 is capable of interaction with cell-surface integrins, we 404 
investigated whether hIGFBP1 activates outside-in integrin-mediated signalling in endothelial 405 
cells. We found that incubation of HUVEC with hIGFBP1 led to acute phosphorylation of the 406 
critical integrin signalling intermediary FAK (fig 8A-B). The non-integrin binding WGD mutant 407 
hIGFBP1 had no effect on FAK phosphorylation (fig 8C-D). Endothelial cell migration is 408 
dependent on cytoskeletal rearrangements in which the small GTPase RhoA plays a critical 409 
role (34). We observed rapid time-dependent activation of RhoA in HUVEC in response to 410 
hIGFBP1 (fig 8E). The cytoskeletal rearrangements associated with endothelial cell motility 411 
are complex, involving formation and dissolution of focal adhesions and the remodelling of 412 
actin filaments. We assessed cytoskeletal remodelling by quantifying actin filament 413 
anisotropy. Incubation with TNF-α led to a significant increase in actin filament anisotropy 414 
which was inhibited by co-incubation with hIGFBP1 (fig 8 F-G).  415 
  416 
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Discussion 417 
This study demonstrated that transgenic expression of hIGFBP1 partially reversed the 418 
endothelial regenerative dysfunction in insulin resistant IR+/-  mice. This was not explained by 419 
modulation of the abundance or function of MACs which are known to be impaired in IR+/- 420 
mice (10). In vitro, we observed favourable effects of hIGFBP1 on multiple endothelial cell 421 
functional properties integral to endothelial regeneration, including increased adhesion to 422 
extracellular matrix and amelioration of the detrimental effects of insulin resistance on 423 
proliferative and migratory responses. At the molecular level, hIGFBP1 induced integrin 424 
signalling through rapid phosphorylation of FAK, increased activity of the small GTPase 425 
RhoA and modulated the effects of the pro-inflammatory cytokine TNF-α on cytoskeletal 426 
remodelling in endothelial cells. Collectively, these findings add further support to the 427 
emerging concept of a vasculo-protective role for IGFBP1 and raise the possibility that 428 
increasing IGFBP1 concentration may be a strategy to improve endothelial repair in insulin 429 
resistant states. 430 
Damage to the vascular endothelium can result from diverse insults including exposure to 431 
the adverse biochemical milieu associated with the presence of vascular risk factors or 432 
mechanical trauma associated with surgical or percutaneous revascularisation procedures. 433 
Endogenous repair mechanisms, which mitigate against the development of atherosclerosis, 434 
thrombosis and restenosis, are deficient in the presence of diabetes (35). We previously 435 
reported that endothelial regeneration following arterial injury was impaired in insulin 436 
resistant mice (IR+/-), in which reduced NO bioavailability and defective mobilisation of MACs 437 
from bone marrow contributed to the reduced abundance of circulating MACs (10). In a 438 
separate study, we reported that hIGFBP1 improved vascular insulin sensitivity and 439 
increased vascular NO bioavailability in IR+/- mice (24). Intriguingly, the enhanced repair 440 
observed in IR+/- mice expressing hIGFBP1 in the current study was not explained by 441 
changes in the abundance or adhesive properties of circulating MACs. Although we cannot 442 
exclude the possibility of changes in other classes of circulating progenitor cells, our data 443 
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suggest that effects of hIGFBP1 on local endothelial cells per se may predominate in the 444 
modulation of endothelial repair. In keeping with this suggestion, the contribution of 445 
circulating progenitor cells to endogenous endothelial regeneration has been drawn in to 446 
question (36,37), reigniting interest in the long-recognised contribution of local, mature 447 
endothelial cells to endothelial repair (5,6,38).  448 
Circulating concentrations of IGFBP1 have been associated with both metabolic regulation 449 
and cardiovascular disease. In non-diabetic humans, low levels of IGFBP1 are predictive of 450 
the subsequent development of diabetes (17–19). However, data linking IGFBP1 levels with 451 
cardiovascular disease development are conflicting (15,22,23) It is, therefore, important to 452 
address whether IGFBP1 directly impacts on the function of vascular cells. We observed a 453 
significant increase in plasma IGFBP1 levels in hIGFBP1-transgenic mice which was 454 
similarly increased in IR+/- mice overexpressing hIGFBP1. The levels achieved in hIGFBP1tg 455 
mice in the current dataset are around two-fold higher than circulating levels in healthy non-456 
obese humans (39), and are substantially higher than those in obese C57BL6 mice (24).  457 
IGFBP1 is known to modulate migratory and/or proliferative responses in a range of cell 458 
types, predominantly through interaction of the RGD sequence within its C-terminal domain 459 
with α5β1 integrin (12,13,40–42)In keeping with a critical impact of the RGD sequence of 460 
IGFBP1 on diverse cellular responses, we recently demonstrated that hIGFBP1 directly 461 
modulates insulin signalling and insulin-stimulated glucose uptake in skeletal muscle cells 462 
through an RGD-dependent mechanism (20). However, this is the first study to report a 463 
modulatory effect of IGFBP1 on functional responses in endothelial cells. Several 464 
fundamental actions pertinent to endothelial repair, including adhesion, migration and 465 
proliferation were favourably modulated by hIGFBP1 in this study.  466 
In an ex-vivo model of endothelial regeneration, short-term incubation with hIGFBP1 467 
significantly increased the proportion of endothelial cells adherent to endothelium-denuded 468 
human saphenous vein. The concentration of hIGFBP1 employed in the cellular experiments 469 
was only slightly higher that the levels achieved in the transgenic mice, indicating that 470 
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important vascular effects of IGFBP1 can be achieved at physiological or modestly supra-471 
physiological concentrations. In keeping with the key role of integrins in the adhesion of 472 
endothelial cells to the extracellular matrix, cell surface expression of integrins αVβ3, αVβ5 473 
and α5β1 was increased after incubation with hIGFBP1.  Interaction of the RGD-motif of 474 
IGFBP1 with integrins is well described (12,13), however this is the first time that IGFBP1 475 
has been reported to increase cell surface integrin expression. Although other members of 476 
the IGF-binding protein family regulate integrin expression at the transcriptional level (43), 477 
the change in cell surface integrin expression observed here is likely to be too rapid to be 478 
explained by transcriptional regulation and may reflect recycling of intracellular integrins to 479 
the cell membrane (44). In vitro, we were unable to identify a dominant ECM component to 480 
which hIGFBP1 preferentially increased endothelial cell adhesion. We speculate that the 481 
pro-adhesive action we observed in saphenous veins ex vivo is either due to additive minor 482 
effects on multiple ECM components or to a selective effect on an ECM constituent we have 483 
not selectively studied.  484 
To determine whether a functional RGD domain of IGFBP1 is essential for its stimulatory 485 
effects on endothelial repair, we mutated RGD to WGD which is incapable of binding 486 
integrins (20). The ability of IGFBP1 to stimulate endothelial cell proliferation and activate 487 
downstream signalling pathways was abrogated by loss of a functional RGD domain. The 488 
findings of the current study therefore add to the growing body of evidence that the IGFBP1-489 
mediated effects in endothelial cells and skeletal muscle are RGD-integrin mediated. 490 
To mimic insulin resistance in vitro, we exposed cells to the cytokine TNF-α. In keeping with 491 
previous reports (45,46), TNF-α inhibited migratory and proliferative responses of endothelial 492 
cells. Incubation with hIGFBP1 partially restored endothelial migration in a scratch wound 493 
assay. However, no effect of hIGFBP1 was evident in the Boyden chamber assay 494 
suggesting that hIGFBP1 augments the motility of endothelial cells rather than acting as a 495 
chemotactic agent in vascular repair. hIGFBP1 was noted to improve endothelial cell 496 
proliferation in the presence of TNF-α.  497 
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It is notable that the favourable effects of hIGFBP1 on endothelial regeneration in this study 498 
were restricted to insulin resistant IR+/- mice with no detectable effect apparent when 499 
hIGFBP1 was expressed in insulin sensitive mice. Similarly, modulatory effects of hIGFBP1 500 
on endothelial proliferative and migratory responses were apparent in vitro only after 501 
inducing insulin resistance by incubation with TNF-α. Although it is possible that the pro-502 
reparative effects of hIGFBP1 were attributable to hIGFBP1-mediated insulin sensitization in 503 
endothelium, as occurs in skeletal muscle (20), this would not readily explain the modulatory 504 
effects of hIGFBP1 observed in vitro which were carried out in the absence of exogenous 505 
insulin. The failure of hIGFBP1 to improve endothelial regeneration in the insulin sensitive 506 
state may, therefore, reflect the fact the reparative processes are already maximal in this 507 
setting. How IGFBP1 interacts with endothelial cells at the molecular level remains poorly 508 
understood. We demonstrated that IGFBP1 induces nitric oxide generation in endothelial 509 
cells independently of IGF by activation of the Akt pathway (24).  Other groups have shown 510 
that IGFBP1 can activate integrin mediated intra-cellular signalling through its C-terminal 511 
RGD sequence and induce migratory or proliferative responses in a range of cell types 512 
including Chinese hamster ovary cells (12), oligodendrocytes (13), trophoblast (40), breast 513 
cancer cells (41) and schwannoma cells (42). In keeping with activation of downstream 514 
integrin signalling by IGFBP1 in the endothelium, we observed rapid RGD-dependent 515 
phosphorylation of focal adhesion kinase (FAK), a non-receptor tyrosine kinase, which 516 
becomes tyrosine-phosphorylated during integrin-activation and is believed to play a vital 517 
role in integrin signal transduction (33,47,48). Inhibition of FAK abrogated the pro-518 
proliferative effects of hIGFBP1. FAK promotes cell migration and angiogenic responses 519 
through interaction with a pool of intracellular signaling proteins, including c-Src, 520 
phosphatidylinositol 3-kinase (PI3-K), and Rho GTPase family members, which are 521 
associated with assembly and disassembly of actin cytoskeleton (49). Coordinated 522 
remodelling of actin filaments through dynamic regulation of filament assembly and 523 
disassembly is required for endothelial cells to mobilise following vascular injury. In response 524 
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to hIGFBP1, we observed rapid and time dependent activation of the small GTPase RhoA 525 
which acts as a key player in cytoskeletal rearrangement and endothelial cell migration (34). 526 
Consistent with the known inhibitory effect of TNF-α on actin remodelling and endothelial cell 527 
migration (50), we observed a significant increase in actin filament anisotropy following TNF-528 
α stimulation. This was abrogated by co-stimulation with hIGFBP1, providing further 529 
evidence that IGFBP1 serves to modulate cytoskeletal remodelling and thereby promote 530 
endothelial repair.  531 
In summary, we have demonstrated that IGFBP1 abrogates the inhibitory effects of insulin 532 
resistance on endothelial repair in vivo and exerts multiple favourable effects on the 533 
reparative phenotype of endothelial cells in vitro. These findings add to our previous 534 
description of insulin-sensitizing and anti-atherosclerotic effects of IGFBP1, are consistent 535 
with the argument that low levels of IGFBP1 being permissive for the development of 536 
vascular disease and suggest that raising IGFBP1 levels may be an appropriate strategy to 537 
promote endothelial repair.   538 
  539 
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Table & Figure Legends 718 
Figure 1 - Endothelial regeneration after wire injury of the femoral artery.  IGFBP-1 719 
rescues endothelial regeneration in insulin resistant mice.  720 
A: Representative in situ Evans blue staining 5 days after vascular injury (blue staining 721 
indicates denuded endothelium) in WT, IGFBP1-tg, IR+/- and IR+/-IGFBP1-tg mice 722 
(magnification ×20).  723 
B: Endothelial regeneration 5 days after vascular injury in WT and IGFBP-1tg mice (n = 7 724 
mice per group).  No significant difference was seen between WT and IGFBP-1tg mice.  725 
C. Endothelial regeneration 5 days post-vascular wire injury, in WT, IR+/- and IR+/-IGFBP1-tg 726 
mice (n = 5-10 per group).  *P < 0.05, **P<0.01 727 
 728 
Figure 2 - Progenitor Cell Abundance and Function. 729 
A-C: Enumeration of myeloid angiogenic cells (MAC) derived from blood, spleen, and bone 730 
marrow by cell culture after 7 days. Numbers of peripheral blood (A) (n=5-6), spleen (B) 731 
(n=6)- and bone marrow (C) (n=6-9)-derived cultured MACs from uninjured mice are shown. 732 
* P < 0.05. HPF=high power field 733 
D. Adhesion capacity of spleen-derived MACs expressed as number of cells adhering to 734 
fibronectin-coated plates (n = 5-6).  No significant difference between groups was observed.   735 
E. Enumeration of circulating Sca-1+/Flk-1+ cells. Number of Sca-1+/Flk-1+ cells were 736 
quantified in peripheral blood by flow cytometry. No significant difference between groups 737 
was identified.  (n=6).  738 
 739 
Figure 3 - hIGFBP1 improves adhesion of human endothelial cells to denuded human 740 
saphenous vein and upregulates cell-surface integrins.  741 
A-B: Representative images of cell-tracker labelled human coronary artery endothelial cells 742 
adherent to denuded saphenous vein after pre-incubation with control medium (A) or 743 
hIGFBP1 (500ng/mL) (B) for 60 minutes. (Magnification - x10).  744 
C: Significantly more cells were adherent to the saphenous vein after pre-incubation with 745 
hIGFBP1 (500ng/mL 60 mins). (n=5) *** P<0.001.  746 
D: Adhesion of human coronary artery endothelial cells to glass cover slips. Human coronary 747 
artery endothelial cells were incubated in 1%FCS +/-hIGFBP1 (500ng/mL) for indicated 748 
times before fixing cells with paraformaldehyde and staining with H&E. Adherent cells were 749 
quantified in 10 random fields at x400 magnification. There were no significant differences 750 
between control and hIGFBP1-treated cells at each time point.  751 
E-F: Cell-surface integrin expression. Human coronary artery endothelial cells were 752 
incubated +/- hIGFBP1 (500ng/mL) for one hour before quantification of cell-surface 753 
integrins using an integrin-mediated cell adhesion array kit (Millipore, MA, USA). Expression 754 
of α-integrins (E) and β-integrins (F) are indicated. (n=6). *P<0.05; **P<0.01.  755 
 756 
 757 
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Figure 4 – hIGFBP1 abrogates TNF-α-induced inhibition of endothelial cell migration  758 
A-B: No significant difference in migration in response to hIGFBP1 (500ng/mL 48h) was 759 
observed in HUVECs (A) or HCAECs (B) in a Scratch wound healing assay. (n=3). 760 
C-D:  Pre-incubation with TNF-α (10ng/mL) for the indicated times inhibited insulin-761 
stimulated (100nmol/L 15 mins) Akt phosphorylation in HUVECs. Representative 762 
immunoblot (C) and mean data of pAkt/Akt ratio (D) are shown.  763 
E-F: hIGFBP1 (500ng/mL) partially restored endothelial migratory responses following 764 
exposure to TNF-α (10mg/mL) in scratch wound assays. E: HUVECs (n=9) *p< 0.01) F: 765 
HCAECs (n=6). *P<0.05. 766 
 767 
Figure 5 - IGFBP-1 does not act as chemotactic agent for endothelial cell migration in 768 
Boyden chamber assays. 769 
A Effect of hIGFBP1 (500ng/mL 6h) on migration in HUVECs, (n=3), no significant difference 770 
was seen  771 
B  Effect of hIGFBP1 (500ng/mL 6h) on migration in HCAECs (n=5), P=0.07   772 
C Effects of IGFBP-1 (500ng/mL 6h) and VEGF (50ng/mL 6h) on cell migration (HCAECs), 773 
(n=5), Control v. VEGF ** P<0.01, VEGF v. VEGF+IGFBP-1 – no significant difference.  774 
 775 
Figure 6 - hIGFBP1 improves endothelial cell proliferation in a pro-inflammatory 776 
setting. 777 
A HUVEC proliferation. Quiesced cells treated with 2.5% FCS supplemented with insulin 778 
(100 nmol/L) or hIGFBP1 (500ng/mL). Cells counted after 5 days with insulin or hIGFBP1 779 
treatment.  (n=4), *p<0.05.  780 
B HCAEC proliferation. Quiesced cells treated with 20% FCS supplemented with either 781 
vehicle or 500ng/mL hIGFBP1. Cells counted after 5 days with control or hIGFBP1 782 
treatment. (n=4).  783 
C Concentration-dependent effect of TNF-α on inhibition of proliferation in HCAECS. Cells 784 
counted after 5 days following TNF-α treatment (0.01-10ng/mL) (n=3) 785 
D HCAEC proliferation. Quiesced cells treated with 20% FCS supplemented with TNF-α 786 
(1ng/mL), hIGFBP1 (500ng/mL) or a combination of TNF-α (1ng/mL) and IGFBP-1 787 
(500ng/mL). Cells counted after 5 days. ANOVA: P<0.01. Post hoc: **P <0.01, *P <0.05 788 
(n=6).  789 
 790 
Figure 7 – IGF-independent effects of hIGFBP1 and involvement its RGD domain and 791 
focal adhesion kinase on endothelial cell proliferation.  792 
A: hIGFBP1 [500ng/L] and IGF-1 [18nM] both independently stimulated proliferation of 793 
HUVEC in an EdU assay. There was no additive effect of IGF-1 and hIGFBP1 on cell 794 
proliferation.  795 
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B&C: Wild-type hIGFBP1 stimulated proliferation of HUVEC. Proliferation was not 796 
significantly increased by hIGFBP1 when the RGD domain was mutated to WGD.  797 
D: The positive effect of hIGFBP1 on proliferation of HUVEC was abrogated by the focal 798 
adhesion kinase inhibitor (FAK-i) PZ0117 (100 nmol/L) (n=4) *P < 0.05 NS=not significant  799 
 800 
Figure 8- hIGFBP1 stimulates phosphorylation of focal adhesion kinase, activates the 801 
small GTPase Rho A and ameliorates TNF-α induced cytoskeletal rearrangement in 802 
endothelial cells 803 
A-B: hIGFBP1 (500ng/mL 15mins) induced rapid 397Tyr phosphorylation of focal adhesion 804 
kinase (FAK) in HUVEC. A: representative immunoblot. B: mean data of pFAK/FAK ratio. 805 
(n=6) *P<0.05. C-D. Mutation of the RGD domain of IGFBP1 to WGD (incapable of integrin-806 
binding) abrogates phosphorylation of FAK. C: representative immunoblot. D. mean data of 807 
pFAK/FAK ratio (n=6). E. hIGFBP1 (500ng/mL) induced time-dependent activation of Rho A 808 
in HCAECs. (n=5) **P<0.01.  F-G: effects of TNF-α (10ng/mL) and hIGFBP1 (500ng/mL) on 809 
actin fibre anisotropy in HUVECs F: representative images (scale bar represents 100 µm). 810 
G: mean data from four repeat experiments with 188-287 cells per experiment *P<0.05, 811 
**P<0.01 812 
 813 
 814 
Antibody Table 815 
List of antibodies used, manufacturer, catalogue number and research resource identifier 816 
(RRID). 817 
 818 
 819 
 820 
821 
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Figures & Tables822 
 823 
 824 
 825 
 826 
 827 
Figure 1 - Endothelial regeneration after wire injury of the femoral artery.  IGFBP-1 828 
rescues endothelial regeneration in insulin resistant mice.  829 
A: Representative in situ Evans blue staining 5 days after vascular injury (blue staining 830 
indicates denuded endothelium) in WT, IGFBP1-tg, IR+/- and IR+/-IGFBP1-tg mice 831 
(magnification ×20).  832 
B: Endothelial regeneration 5 days after vascular injury in WT and IGFBP-1tg mice (n = 7 833 
mice per group).  No significant difference was seen between WT and IGFBP-1tg mice.  834 
C. Endothelial regeneration 5 days post-vascular wire injury, in WT, IR+/- and IR+/-IGFBP1-tg 835 
mice (n = 5-10 per group).  *P < 0.05, **P<0.01 836 
  837 
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 838 
Figure 2 - Progenitor Cell Abundance and Function. 839 
A-C: Enumeration of myeloid angiogenic cells (MAC) derived from blood, spleen, and bone 840 
marrow by cell culture after 7 days. Numbers of peripheral blood (A) (n=5-6), spleen (B) 841 
(n=6)- and bone marrow (C) (n=6-9)-derived cultured MACs from uninjured mice are shown. 842 
* P < 0.05. HPF=high power field 843 
D. Adhesion capacity of spleen-derived MACs expressed as number of cells adhering to 844 
fibronectin-coated plates (n = 5-6).  No significant difference between groups was observed.   845 
E. Enumeration of circulating Sca-1+/Flk-1+ cells. Number of Sca-1+/Flk-1+ cells were 846 
quantified in peripheral blood by flow cytometry. No significant difference between groups 847 
was identified.  (n=6).  848 
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 852 
 853 
 854 
Figure 3 - hIGFBP1 improves adhesion of human endothelial cells to denuded human 855 
saphenous vein and upregulates cell-surface integrins.  856 
A-B: Representative images of cell-tracker labelled human coronary artery endothelial cells 857 
adherent to denuded saphenous vein after pre-incubation with control medium (A) or 858 
hIGFBP1 (500ng/mL) (B) for 60 minutes. (Magnification - x10).  859 
C: Significantly more cells were adherent to the saphenous vein after pre-incubation with 860 
hIGFBP1 (500ng/mL 60 mins). (n=5) *** P<0.001.  861 
D: Adhesion of human coronary artery endothelial cells to glass cover slips. Human coronary 862 
artery endothelial cells were incubated in 1%FCS +/-hIGFBP1 (500ng/mL) for indicated 863 
times before fixing cells with paraformaldehyde and staining with H&E. Adherent cells were 864 
quantified in 10 random fields at x400 magnification. There were no significant differences 865 
between control and hIGFBP1-treated cells at each time point.  866 
E-F: Cell-surface integrin expression. Human coronary artery endothelial cells were 867 
incubated +/- hIGFBP1 (500ng/mL) for one hour before quantification of cell-surface 868 
integrins using an integrin-mediated cell adhesion array kit (Millipore, MA, USA). Expression 869 
of α-integrins (E) and β-integrins (F) are indicated. (n=6). *P<0.05; **P<0.01.  870 
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 871 
Figure 4 – hIGFBP1 abrogates TNF-α-induced inhibition of endothelial cell migration  872 
A-B: No significant difference in migration in response to hIGFBP1 (500ng/mL 48h) was 873 
observed in HUVECs (A) or HCAECs (B) in a Scratch wound healing assay. (n=3).C-D:  874 
Pre-incubation with TNF-α (10ng/mL) for the indicated times inhibited insulin-stimulated 875 
(100nmol/L 15 mins) Akt phosphorylation in HUVECs. Representative immunoblot (C) and 876 
mean data of pAkt/Akt ratio (D) are shown. E-F: hIGFBP1 (500ng/mL) partially restored 877 
endothelial migratory responses following exposure to TNF-α (10mg/mL) in scratch wound 878 
assays. E: HUVECs (n=9) *p< 0.01) F: HCAECs (n=6). *P<0.05. 879 
 880 
  881 
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 882 
Figure 5 - IGFBP-1 does not act as chemotactic agent for endothelial cell migration in 883 
Boyden chamber assays. 884 
A Effect of hIGFBP1 (500ng/mL 6h) on migration in HUVECs, (n=3), no significant difference 885 
was seen  886 
B  Effect of hIGFBP1 (500ng/mL 6h) on migration in HCAECs (n=5), P=0.07   887 
C Effects of IGFBP-1 (500ng/mL 6h) and VEGF (50ng/mL 6h) on cell migration (HCAECs), 888 
(n=5), Control v. VEGF ** P<0.01, VEGF v. VEGF+IGFBP-1 – no significant difference.  889 
  890 
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 891 
 892 
Figure 6 - hIGFBP1 improves endothelial cell proliferation in a pro-inflammatory 893 
setting. 894 
A HUVEC proliferation. Quiesced cells treated with 2.5% FCS supplemented with insulin 895 
(100 nmol/L) or hIGFBP1 (500ng/mL). Cells counted after 5 days with insulin or hIGFBP1 896 
treatment.  (n=4), *p<0.05.  897 
B HCAEC proliferation. Quiesced cells treated with 20% FCS supplemented with either 898 
vehicle or 500ng/mL hIGFBP1. Cells counted after 5 days with control or hIGFBP1 899 
treatment. (n=4).  900 
C Concentration-dependent effect of TNF-α on inhibition of proliferation in HCAECS. Cells 901 
counted after 5 days following TNF-α treatment (0.01-10ng/mL) (n=3) 902 
D HCAEC proliferation. Quiesced cells treated with 20% FCS supplemented with TNF-α 903 
(1ng/mL), hIGFBP1 (500ng/mL) or a combination of TNF-α (1ng/mL) and IGFBP-1 904 
(500ng/mL). Cells counted after 5 days. ANOVA: P<0.01. Post hoc: **P <0.01, *P <0.05 905 
(n=6).  906 
 907 
 908 
909 
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 Figure 7 – IGF-independent effects of hIGFBP1 and involvement its RGD domain and 910 
focal adhesion kinase on endothelial cell proliferation.  911 
A: hIGFBP1 [500ng/L] and IGF-1 [18nM] both independently stimulated proliferation of 912 
HUVEC in an EdU assay. There was no additive effect of IGF-1 and hIGFBP1 on cell 913 
proliferation. B&C: Wild-type hIGFBP1 stimulated proliferation of HUVEC. Proliferation was 914 
not significantly increased by hIGFBP1 when the RGD domain was mutated to WGD. D: The 915 
positive effect of hIGFBP1 on proliferation of HUVEC was abrogated by the focal adhesion 916 
kinase inhibitor (FAK-i) PZ0117 (100 nmol/L) (n=4) *P < 0.05 NS=not significant  917 
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 919 
Figure 8- hIGFBP1 stimulates phosphorylation of focal adhesion kinase, activates the 920 
small GTPase Rho A and ameliorates TNF-α induced cytoskeletal rearrangement in 921 
endothelial cells 922 
A-B: hIGFBP1 (500ng/mL 15mins) induced rapid 397Tyr phosphorylation of focal adhesion 923 
kinase (FAK) in HUVEC. A: representative immunoblot. B: mean data of pFAK/FAK ratio. 924 
(n=6) *P<0.05. C-D. Mutation of the RGD domain of IGFBP1 to WGD (incapable of integrin-925 
binding) abrogates phosphorylation of FAK. C: representative immunoblot. D. mean data of 926 
pFAK/FAK ratio (n=6). E. hIGFBP1 (500ng/mL) induced time-dependent activation of Rho A 927 
in HCAECs. (n=5) **P<0.01.  F-G: effects of TNF-α (10ng/mL) and hIGFBP1 (500ng/mL) on 928 
actin fibre anisotropy in HUVECs F: representative images (scale bar represents 100 µm). 929 
G: mean data from four repeat experiments with 188-287 cells per experiment *P<0.05, 930 
**P<0.01 931 
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Antibody Table 933 
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Supplementary Figures 951 
 952 
 953 
Supplementary Figure 1 – Plasma concentration of IGFBP1 in mice. Plasma IGFBP1 954 
level was measured by ELISA in wild type mice, mice heterozygous for deletion of the insulin 955 
receptor (IR+/-) and IGFBP1 transgenic (-tg) mice.  (n=6-15)  *P < 0.05, **P<0.01, NS=not 956 
significant. 957 
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 959 
 960 
Supplementary Figure 2 – Effects of hIGFBP1 on adhesion of endothelial cells to 961 
extracellular matrix constituents. HUVEC were incubated with hIGFBP1 (500ng/mL 60 962 
mins) before quantifying adhesion to the following matrix components: A: fibronectin; B: 963 
collagen I; C: vitronectin; D: collagen IV. There was a non-specific trend to increased 964 
adhesion in response to hIGFBP1 but none of the effects on adhesion to individual 965 
components reached statistical significance. Inhibition of focal adhesion kinase (FAK-i) did 966 
not influence the adhesion of unstimulated cells (D). Adhesion to collagen IV in the presence 967 
of hIGFBP1 was significantly reduced by inhibition of focal adhesion kinase (D) (n=4-8) 968 
P<0.05. 969 
  970 
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  971 
Supplementary Figure 3 – Concentration-dependence of hIGFBP1-stimulated 972 
endothelial cell proliferation.  973 
HUVEC proliferation was quantified with an EdU assay after incubation with hIGFBP1 at the 974 
indicated concentrations. Stimulation of proliferation by hIGFBP1 reached statistical 975 
significance at 100-500ng/mL (n=3) *P < 0.05  976 
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